Glycoproteins (Glycoprotein)

Conjugated protein-carbohydrate compounds including MUCINS; mucoid, and AMYLOID glycoproteins.

Also Known As:

Glycoprotein; Neoglycoproteins; Protein, Glycosylated; Proteins, C-Glycosylated; Proteins, Glycosylated; Proteins, N-Glycosylated; Proteins, O-Glycosylated; C-Glycosylated Proteins; Glycosylated Protein; Glycosylated Proteins; N-Glycosylated Proteins; O-Glycosylated Proteins

Networked: 24834 relevant articles (645 outcomes, 2145 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Stone, Gregg W: 79 articles (01/2022 - 10/2003)
2.	Mehran, Roxana: 65 articles (02/2020 - 10/2003)
3.	Feldmann, Heinz: 57 articles (06/2021 - 01/2003)
4.	Zhang, Hui: 51 articles (03/2022 - 02/2006)
5.	Lim, Kye-Taek: 50 articles (01/2021 - 12/2004)
6.	Geisbert, Thomas W: 44 articles (01/2022 - 06/2005)
7.	Marzi, Andrea: 41 articles (03/2022 - 11/2004)
8.	Nieswandt, Bernhard: 35 articles (12/2022 - 04/2003)
9.	Gibson, C Michael: 35 articles (08/2021 - 11/2002)
10.	Montalescot, Gilles: 35 articles (01/2020 - 10/2002)

Related Diseases

1.	Infections 01/01/2016 - "Therefore, the MACV strain expressing the glycoprotein of Candid#1 is safe, genetically stable, and highly protective against MACV infection in a mouse model. " 12/01/2015 - "Glycoproteins of human milk are multifunctional molecules, and their fucosylated variants are potentially active molecules in immunological events ensuring breastfed infants optimal development and protection against infection diseases. " 06/01/1990 - "Antibody mediated and cell mediated immune responses to the envelope glycoproteins gp120 and gp41 of the human immunodeficiency virus (HIV-1) are considered important for protection against infection and for attenuation of disease symptoms after infection. " 10/01/2022 - "To establish effective means to prevent MSRV infection, the pcDNA3.1-G plasmid containing the MSRV glycoprotein gene was successfully constructed and intramuscularly injected into the largemouth bass to evaluate the immune responses and protective effects in our study. " 11/01/2008 - "colubriformis glycoprotein Tc-120 and CarLA were tested in the passive immunity model and it was found that only the antibody against CarLA resulted in a significant reduction of infection (87%). "
2.	Neoplasms (Cancer) 10/04/2022 - "In view of its high sensitivity and selectivity, simple operation, and cost-friendliness, the eATRP-based electrochemical aptasensor shows great promise in the glycoprotein-based liquid biopsy of malignant tumors, even at the early stage of development." 01/01/1979 - "Administration of this glycoprotein has resulted in significant reduction of tumor mass in more than half of all patients treated up to this time." 02/01/1994 - "In addition, DHE was slightly more effective in purging tumor cells expressing the p-170 glycoprotein.(ABSTRACT TRUNCATED AT 250 WORDS)" 02/01/1993 - "In addition, DHE was slightly more effective in purging tumor cells expressing the p-170 glycoprotein. " 02/01/1977 - "Measurement of urinary glycoprotein EDCl will be useful in rapidly ascertaining which drug will be effective in a cancer patient and in predicting relapse."
3.	Acute Coronary Syndrome 09/01/2011 - "Glycoprotein IIb/IIIa antagonists are effective for the treatment of acute coronary syndromes proven in large clinical trials. " 01/01/1999 - "The results of different clinical studies show evidence that glycoprotein IIb-IIIa antagonists, given intravenously, are effective in the management of acute coronary intervention with high thrombogenic risk, and also help to control the early phase of acute coronary syndromes. " 07/11/2000 - "Although intravenous glycoprotein IIb/IIIa inhibitors are beneficial in patients with acute coronary syndromes, prolonged oral IIb/IIIa inhibition might provide an additional reduction in recurrent events. " 04/01/1998 - "Clinical trials with the glycoprotein IIb/IIIa inhibitors have suggested that this class of agents may be particularly effective in reducing the thrombotic complications associated with coronary interventional procedures and may be useful in the treatment of acute coronary syndromes." 04/01/1998 - "Clinical trials with the glycoprotein IIb/IIIa inhibitors have suggested that this class of agents may be particularly effective in reducing the thrombotic complications associated with coronary interventional procedures and may be useful in the treatment of acute coronary syndromes."
4.	Myocardial Infarction 12/15/2012 - "We investigated whether additional platelet inhibition with a glycoprotein IIb/IIIa inhibitor would be beneficial in reducing the risk of periprocedural myocardial infarction (PMI) in diabetic patients with high residual platelet reactivity (HPR). " 04/01/2002 - "Glycoprotein receptor antagonists have been beneficial in patients undergoing percutaneous transluminal coronary angioplasty; however, little is known about their potency of inducing reperfusion in acute myocardial infarction. " 08/01/2003 - "Coronary stenting and the use of glycoprotein IIb/IIIa inhibitors have also improved the immediate results in patients with acute myocardial infarction (AMI) undergoing primary PTCA. " 01/01/2019 - "Glycoprotein IIb/IIIa inhibitor use in patients with acute myocardial infarction undergoing PCI: Insights from the TRANSLATE ACS study." 07/01/2008 - "The present study was undertaken to evaluate the preventive role of SACS on some biochemical parameters, glycoproteins and hematology in experimentally induced myocardial infarction in rats. "
5.	Hemorrhage 05/01/2011 - "Glycoprotein IIb-IIIa receptor inhibitors, although they are highly effective in preventing ischemic events, must be used with care to reduce bleeding risk. " 07/01/2006 - "Although glycoprotein IIb/IIIa inhibitors appear to be beneficial in select cases, bleeding concerns exist. " 03/15/2023 - "In this study, we aimed to compare the expression level of glycoprotein (GP)Ib-IX-V platelet receptor complex in HeartMate 3 (HM 3) patients with and without bleeding complications to investigate the alterations of the platelet transcriptomic profile on platelet damage and increased bleeding risk. " 01/01/2020 - "Recent studies have implicated elevated soluble glycoprotein VI (sGPVI) levels as a potential risk factor for bleeding. " 01/01/2008 - "While awaiting the results of a few other currently ongoing trials, facilitated PCI should now probably be restricted to the administration of glycoprotein IIb-IIIa inhibitors for patients at high risk of cardiovascular events and at low risk of bleeding when a more than 60-minute delay to primary PCI is anticipated. "

Related Drugs and Biologics

1.	Vaccines
2.	Proteins (Proteins, Gene)
3.	Heparin (Liquaemin)
4.	bivalirudin (Angiomax)
5.	Monoclonal Antibodies
6.	Platelet Membrane Glycoprotein IIb
7.	Neutralizing Antibodies
8.	Antibodies
9.	Antigens
10.	Subunit Vaccines

Related Therapies and Procedures

1.	Percutaneous Coronary Intervention
2.	Therapeutics
3.	Stents
4.	Drug Therapy (Chemotherapy)
5.	Catheters